TABLE 2.
Clinical and pathological information of patients in the validation cohort
| HC (n = 30) | BCa patients (n = 40) | P | |
|---|---|---|---|
| Age (y), median (range) | 57 (41‐74) | 71 (31‐87) | <.001 |
| Gender, n (%) | |||
| Male | 17 (56.7) | 29 (72.5) | .167 |
| Female | 13 (43.3) | 11 (27.5) | |
| Urine cytology, n (%) | |||
| Negative | 30 (100) | 20 (50.0) | <.001 |
| Positive | 0 (0) | 19 (47.5) | |
| Unknown | 1 (2.5) | ||
| Pathological T stage n, (%) | |||
| pTa | – | 20 (50.0) | |
| pT2 ≤ | – | 20 (50.0) | |
| Pathological grade, n (%) | |||
| Low grade | – | 12 (30.0) | |
| High grade | – | 28 (70.0) | |
Abbreviations: BCa, bladder cancer; HC, healthy controls.